Product image of Meriofert Set (Follicle-Stimulating Hormone, Luteinising Hormone) supplied by GNH India

Meriofert Set

Active Ingredient:
Follicle-Stimulating Hormone, Luteinising Hormone
Origin:
EU

Meriofert Set (Follicle-Stimulating Hormone, Luteinising Hormone)

Follicle‑Stimulating Hormone and Luteinising Hormone, the active ingredients in Meriofert Set, are gonadotropins presented as an injectable solution for subcutaneous use. They are employed to induce ovulation in women with anovulation or oligo‑ovulation and to support controlled ovarian stimulation during assisted reproductive technology cycles and to aid luteal phase support in fertility treatment protocols.

GNH India supplies Meriofert Set as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for biologic products.

Manufacturer / TM Owner

Ibsa Farmaceutici Italia

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Meriofert Set, a gonadotropin used in reproductive endocrinology, is indicated for the following clinical situations:

  • Induction of ovulation: facilitates follicular development and ovulation in women with anovulation or oligo‑ovulation.
  • Controlled ovarian stimulation: enhances multiple follicle growth for assisted reproductive technology procedures.
  • Luteal phase support: supports corpus luteum function during fertility treatment protocols.
  • Polycystic ovary syndrome (PCOS) treatment: promotes follicular maturation to achieve regular ovulation in PCOS patients.
  • In vitro fertilization (IVF) cycles: increases oocyte yield to improve embryo availability for IVF.

How It Works

  • Follicle‑Stimulating Hormone (FSH) and Luteinising Hormone (LH) bind to their respective receptors on ovarian granulosa and theca cells. Activation of FSH receptors stimulates follicular growth and estrogen synthesis, while LH receptor activation promotes the final maturation of the dominant follicle and luteinisation, leading to ovulation and support of the luteal phase.

Side Effects

Common Side Effects

  • Injection site reactions: pain, redness, or swelling at the injection site.
  • Mild ovarian hyperstimulation syndrome: abdominal discomfort, bloating, and mild weight gain.
  • Headache.
  • Nausea.
  • Fatigue.

Serious or Rare Side Effects

  • Severe ovarian hyperstimulation syndrome: rapid weight gain, shortness of breath, thrombosis, or renal impairment.
  • Allergic reaction: rash, urticaria, or anaphylaxis.
  • Ovarian torsion: sudden pelvic pain requiring emergency intervention.

Precautions & Warnings

Meriofert Set should be used with careful clinical monitoring:

  • Pregnancy testing: confirm non‑pregnant status before initiating therapy.
  • Monitor ovarian response: use ultrasound and estradiol levels to adjust dosing.
  • Risk of OHSS: assess risk factors and limit stimulation in high‑risk patients.
  • Allergy history: avoid if known hypersensitivity to gonadotropins.
  • Concomitant medications: review for drugs affecting ovarian response.
  • Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Meriofert Set may interact with other agents affecting ovarian function.

Major Interactions (Avoid)

  • Human chorionic gonadotropin (hCG): may exacerbate ovarian hyperstimulation; avoid concurrent use.
  • Estrogen‑containing oral contraceptives: can suppress endogenous gonadotropin response; discontinue before treatment.
  • GnRH agonists used for down‑regulation: timing must be coordinated; avoid overlapping.

Moderate Interactions (Monitor Closely)

  • Clomiphene citrate: may alter follicular response; monitor estradiol levels.
  • Letrozole: may affect ovarian stimulation; adjust dose as needed.
  • Thyroid hormone replacement: monitor thyroid function as gonadotropins can influence hormone metabolism.

Frequently Asked Questions

Meriofert Set is a gonadotropin preparation used to induce ovulation in women with anovulation or oligo‑ovulation, to support controlled ovarian stimulation in assisted reproductive technology cycles, and to provide luteal phase support during fertility treatment protocols.

FSH binds to receptors on ovarian granulosa cells, promoting follicular growth and estrogen production, while LH binds to theca‑cell receptors, triggering final follicle maturation, ovulation and luteinisation. Together they coordinate the hormonal cascade required for successful ovulation and early luteal function.

The dose of Meriofert Set is individualized and determined by the prescribing physician based on the patient’s ovarian response, treatment protocol and clinical goals. Specific dosing regimens are not disclosed publicly and should follow the prescriber’s instructions.

Meriofert Set is intended for use before conception to facilitate ovulation and is not indicated for use during an established pregnancy. Safety data for breastfeeding are limited; patients should discuss potential risks with their healthcare provider before using the product.

To order Meriofert Set, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Meriofert Set contains both FSH and LH, similar to combination products such as Menopur, whereas some alternatives provide only FSH (e.g., Gonal‑F). The combined formulation may simplify dosing for protocols that require both hormones, but selection depends on physician preference, patient response and specific treatment plans.

Meriofert Set should be stored at 2 °C to 8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Follow the manufacturer’s cold‑chain guidelines during transport and handling.

Meriofert Set is administered by subcutaneous injection, typically into the abdominal wall or thigh. The injection technique should follow aseptic procedures, using a sterile needle and syringe, and be performed by a trained healthcare professional or under medical supervision.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can cause rapid weight gain, shortness of breath and thrombotic events, as well as ovarian torsion and severe allergic reactions such as anaphylaxis. Patients should be monitored closely for these complications.

Meriofert Set should not be used in women who are already pregnant, have known hypersensitivity to gonadotropins, have uncontrolled thyroid disease, or have active ovarian cysts that could increase the risk of OHSS. Contra‑indications should be confirmed by the prescribing clinician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Follicle-Stimulating Hormone, Luteinising Hormone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT